LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Omeros Corp

Fechado

SetorSaúde

3.8 15.5

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.28

Máximo

3.84

Indicadores-chave

By Trading Economics

Rendimento

-2.1M

-33M

Vendas

412K

412K

EPS

-0.541

Margem de lucro

-8,121.359

Funcionários

202

EBITDA

-1.9M

-35M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+1263.64% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-242M

180M

Abertura anterior

-11.7

Fecho anterior

3.8

Sentimento de Notícias

By Acuity

40%

60%

129 / 380 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Omeros Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

6 de jun. de 2025, 14:31 UTC

Ganhos

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

6 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

6 de jun. de 2025, 20:33 UTC

Ganhos

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 de jun. de 2025, 19:36 UTC

Conversa de Mercado

Oil Futures Post Solid Weekly Gains -- Market Talk

6 de jun. de 2025, 19:28 UTC

Conversa de Mercado

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 de jun. de 2025, 18:46 UTC

Conversa de Mercado

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 de jun. de 2025, 18:02 UTC

Conversa de Mercado

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 de jun. de 2025, 16:35 UTC

Ganhos

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 de jun. de 2025, 16:34 UTC

Ganhos

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 de jun. de 2025, 16:21 UTC

Conversa de Mercado

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

6 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

6 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

6 de jun. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

6 de jun. de 2025, 16:07 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

6 de jun. de 2025, 16:07 UTC

Conversa de Mercado

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 de jun. de 2025, 15:53 UTC

Conversa de Mercado

Mexican Inflation Seen Rising in May -- Market Talk

6 de jun. de 2025, 15:36 UTC

Conversa de Mercado

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 de jun. de 2025, 15:36 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 de jun. de 2025, 15:33 UTC

Conversa de Mercado

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 de jun. de 2025, 15:16 UTC

Conversa de Mercado

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 de jun. de 2025, 15:05 UTC

Conversa de Mercado

Silver at its Highest In Nearly 15 Years -- Market Talk

6 de jun. de 2025, 14:35 UTC

Conversa de Mercado

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 de jun. de 2025, 14:28 UTC

Conversa de Mercado

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 de jun. de 2025, 14:28 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 de jun. de 2025, 14:28 UTC

Conversa de Mercado

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 de jun. de 2025, 14:15 UTC

Conversa de Mercado

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 de jun. de 2025, 14:12 UTC

Ganhos

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 de jun. de 2025, 14:09 UTC

Ganhos

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Comparação entre Pares

Variação de preço

Omeros Corp Previsão

Preço-alvo

By TipRanks

1263.64% parte superior

Previsão para 12 meses

Média 45 USD  1263.64%

Máximo 45 USD

Mínimo 45 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Omeros Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

1

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

6.265 / 7.49Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bullish Evidence

Sentimento

By Acuity

129 / 380 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.